Generic Duetact® Launches

Released: 01/15/2013   By: Mike Partridge, RPh

On January 8, 2013, Sandoz received final FDA approval for and commenced shipping the generic equivalent for Takeda’s branded product, Duetact® (pioglitazone HCL) tablets. Duetact® had estimated total U.S. annual sales of approximately $30 million.

Duetact is an oral antihyperglyemic agent that acts primarily by decreasing insulin resistance, and is used in the management of type 2 diabetes.